In sum, Novartis accused Alexion of launching “a false and misleading marketing campaign that is unsupported by scientific ...

Omeros Corporation (NASDAQ:OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and ...

Pregnancy exacerbates PNH-related manifestations. Complement inhibition has improved both maternal and fetal outcomes. Most hematologists agree that the benefits of complement inhibition during ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug.

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Clone size and symptom burden dictate how often patients with PNH require follow-up. Hematology assessments during routine visits should include flow cytometry, CBC, D-dimer levels, and serum ferritin ...

A retrospective analysis suggested that immune cells play a role in the progression of paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, as Daria Babushok, Division of Hematology-Oncology, ...

Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...